Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry-Reference-Cited by-同舟云学术

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry

Published:2015-05-06 Issue:9 Volume:29 Page:1875-1881
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bernal T, ,Martínez-Camblor P,Sánchez-García J,de Paz R,Luño E,Nomdedeu B,Ardanaz M T,Pedro C,Amigo M L,Xicoy B,del Cañizo C,Tormo M,Bargay J,Valcárcel D,Brunet S,Benlloch L,Sanz G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015115.pdf

Reference22 articles.

1. Tefferi A, Vardiman JW . Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–1885.

2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

3. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503–3510.

5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

2. Unveiling sex-based geographical disparities in myelodysplastic syndrome mortality trends in Spain (1999–2022);Clinical and Translational Oncology;2024-05-19

3. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis;Cancers;2024-03-29

4. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review;Journal of Oncology Pharmacy Practice;2024-03-21

5. Full-Dose Azacitidine in 5 Days Versus 7 Days With a Weekend Break in Myelodysplastic Syndromes: A Retrospective Cohort Study;Clinical Lymphoma Myeloma and Leukemia;2024-02